Neurocrine Biosciences (NBIX) Cash & Current Investments (2010 - 2026)

Neurocrine Biosciences' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• Quarterly Cash & Current Investments rose 39.5% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 39.5% YoY) and the FY2025 annual result came in at $1.5 billion, up 37.57% from the prior year.
• Cash & Current Investments was $1.3 billion for Q1 2026 at Neurocrine Biosciences, down from $1.5 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $1.5 billion in Q4 2025 and bottomed at $648.3 million in Q2 2022.
• A 5-year average of $1.0 billion and a median of $1.0 billion in 2024 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments declined 26.74% — and 2023, when it surged 50.66%.
• Neurocrine Biosciences' Cash & Current Investments stood at $997.1 million in 2022, then increased by 4.26% to $1.0 billion in 2023, then advanced by 3.51% to $1.1 billion in 2024, then jumped by 37.57% to $1.5 billion in 2025, then retreated by 11.09% to $1.3 billion in 2026.
• Business Quant data shows NBIX's Cash & Current Investments at $1.3 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.1 billion in Q3 2025.